NCT00728390 2024-04-22A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 WeeksPfizerPhase 1 Completed74 enrolled
NCT00783328 2011-06-27A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid TumorsPfizerPhase 1 Completed13 enrolled